Race Oncology Limited has discovered several new potential candidates for FTO inhibitors

Race Oncology Limited (ASX: RAC) reached a remarkable milestone in its research journey by completing an FTO-targeted drug discovery program at Monash University’s Fragment Platform. Through state-of-the-art NMR fragment-based screening, the company has successfully identified 39 promising molecular candidates—hits—targeting the m6A RNA demethylase protein, FTO. These validated FTO-binding chemical scaffolds not only lay a strong foundation for innovative and patentable drug development but also hold the potential to transform treatments targeting the m6A RNA epigenetic pathway.

Confirming these compounds’ structures for developing cutting-edge FTO-targeting therapies represents a significant advancement in the field. This progress paves the way for creating valuable new intellectual property, opening opportunities for novel drugs that could change the treatment landscape for disorders linked to the m6A RNA epigenetic pathway.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com